Summary & Overview
CPT 00148: Anesthesia for Eye Examination Using Endoscope
CPT code 00148 represents anesthesia for eye examinations performed with an endoscope, a specialized procedure that supports accurate diagnosis and management of ocular conditions. This code is significant for both clinical and billing teams, as it defines the scope of anesthesia services required for endoscopic eye exams and is recognized by major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
The publication provides a comprehensive overview of CPT 00148, detailing its clinical context, typical sites of service, and its role within the broader anesthesiology service line. Readers will gain insights into payer coverage, relevant policy updates, and benchmarks for anesthesia services in ophthalmology. The article also highlights associated modifiers and taxonomies, as well as related CPT codes and ICD-10 diagnoses commonly linked to this procedure. This information is essential for understanding reimbursement trends, compliance requirements, and the evolving landscape of anesthesia billing for eye examinations using endoscopic techniques.
CPT Code Overview
CPT 00148 is used to report anesthesia services provided for eye examinations utilizing an endoscope. This code falls under the anesthesiology service type and is typically performed in a surgery center or hospital outpatient setting. The procedure involves the administration of anesthesia to facilitate a thorough endoscopic examination of the eye, ensuring patient comfort and safety during the diagnostic process.
Clinical & Coding Specifications
Clinical Context
A patient presents to a surgery center or hospital outpatient department for an eye examination requiring the use of an endoscope. The procedure is indicated due to suspected adverse effects from medications acting on muscles or the respiratory system, or from local antifungal, anti-infective, anti-inflammatory drugs, or antipruritics. The patient may have experienced symptoms such as vision changes, pain, or other ocular complications. An anesthesiology physician or certified registered nurse anesthetist (CRNA) provides anesthesia services to ensure patient comfort and safety during the endoscopic eye examination. The clinical workflow involves pre-procedure assessment, administration of anesthesia, monitoring throughout the procedure, and post-procedure recovery.
Coding Specifications
-
Modifiers:
QS: Monitored anesthesia care service. Used when anesthesia is provided with continuous monitoring but not general anesthesia.QX: CRNA service with medical direction by a physician. Used when a CRNA is medically directed by an anesthesiology physician.
-
Provider Taxonomies:
Taxonomy Code Specialty 207L00000XAnesthesiology Physician 367500000XCertified Registered Nurse Anesthetist 207W00000XOphthalmology Physician -
Service Type:
- Anesthesiology
-
Typical Site of Service:
- Surgery Center or Hospital Outpatient (POS 22)
Related Diagnoses
-
T48.205S: Adverse effect of unspecified drugs acting on muscles, sequela- Relevant when the eye examination is performed to assess sequelae from drug effects on ocular muscles.
-
T48.295A: Adverse effect of other drugs acting on muscles, initial encounter- Used when the procedure is indicated due to an initial adverse drug effect on eye muscles.
-
T48.295D: Adverse effect of other drugs acting on muscles, subsequent encounter- Applied for follow-up procedures after an initial adverse drug effect.
-
T48.295S: Adverse effect of other drugs acting on muscles, sequela- Used for long-term complications from drug effects on eye muscles.
-
T48.3X5A: Adverse effect of antitussives, initial encounter- Relevant if antitussive medications caused ocular symptoms requiring endoscopic examination.
-
T48.3X5D: Adverse effect of antitussives, subsequent encounter- Used for follow-up after initial adverse effect from antitussives.
-
T48.3X5S: Adverse effect of antitussives, sequela- Applied for sequelae from antitussive drug effects.
-
T48.4X5A: Adverse effect of expectorants, initial encounter- Used when expectorants cause adverse ocular effects.
-
T48.4X5D: Adverse effect of expectorants, subsequent encounter- For follow-up after initial expectorant-related adverse effect.
-
T48.4X5S: Adverse effect of expectorants, sequela- Used for sequelae from expectorant drug effects.
-
T48.5X5A: Adverse effect of other anti-common-cold drugs, initial encounter- Relevant for initial adverse effects from anti-common-cold drugs affecting the eye.
-
T48.5X5D: Adverse effect of other anti-common-cold drugs, subsequent encounter- Used for follow-up procedures.
-
T48.5X5S: Adverse effect of other anti-common-cold drugs, sequela- Applied for sequelae from these drugs.
-
T48.6X5A: Adverse effect of antiasthmatics, initial encounter- Used when antiasthmatic drugs cause ocular adverse effects.
-
T48.6X5D: Adverse effect of antiasthmatics, subsequent encounter- For follow-up after initial adverse effect.
-
T48.6X5S: Adverse effect of antiasthmatics, sequela- Used for sequelae from antiasthmatic drug effects.
-
T48.905A: Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter- Relevant for initial adverse effects from unspecified respiratory agents.
-
T48.905D: Adverse effect of unspecified agents primarily acting on the respiratory system, subsequent encounter- Used for follow-up procedures.
-
T48.905S: Adverse effect of unspecified agents primarily acting on the respiratory system, sequela- Applied for sequelae from these agents.
-
T48.995A: Adverse effect of other agents primarily acting on the respiratory system, initial encounter- Used for initial adverse effects from other respiratory agents.
-
T48.995D: Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter- For follow-up after initial adverse effect.
-
T48.995S: Adverse effect of other agents primarily acting on the respiratory system, sequela- Used for sequelae from these agents.
-
T49.0X5A: Adverse effect of local antifungal, anti‑infective and anti‑inflammatory drugs, initial encounter- Relevant when these drugs cause ocular adverse effects.
-
T49.0X5D: Adverse effect of local antifungal, anti‑infective and anti‑inflammatory drugs, subsequent encounter- Used for follow-up procedures.
-
T49.0X5S: Adverse effect of local antifungal, anti‑infective and anti‑inflammatory drugs, sequela- Applied for sequelae from these drugs.
-
T49.1X5A: Adverse effect of antipruritics, initial encounter- Used when antipruritics cause adverse ocular effects.
-
T49.1X5D: Adverse effect of antipruritics, subsequent encounter- For follow-up after initial adverse effect.
-
T49.1X5S: Adverse effect of antipruritics, sequela- Used for sequelae from antipruritic drug effects.
Related CPT Codes
| CPT Code | Description | Clinical Relationship |
|---|---|---|
00140 | Anesthesia for procedures on eye; not otherwise specified | Used for general eye procedures requiring anesthesia; alternative to 00148 when endoscope is not used |
00142 | Anesthesia for procedures on eye; lens surgery | Used for lens surgery; may be used instead of 00148 if procedure involves lens rather than endoscopic examination |
00144 | Anesthesia for procedures on eye; corneal transplant | Used for corneal transplant procedures; alternative to 00148 for corneal surgery |
00145 | Anesthesia for procedures on eye; vitreoretinal surgery | Used for vitreoretinal surgery; may be used in place of 00148 if procedure is focused on retina or vitreous |
00147 | Anesthesia for procedures on eye; iridectomy | Used for iridectomy procedures; alternative to 00148 for iris surgery |
These codes are related to 00148 and may be used as alternatives depending on the specific eye procedure performed. They are not typically used together but represent anesthesia services for different types of eye surgeries.
National Reimbursement Benchmarks
National mean rates for CPT code 00148 show that commercial payers, as represented by BUCA, average $114.59, while Medicare rates are not available in the input. Among individual commercial payers, Cigna has the highest mean rate at $249.00, followed by Blue Cross Blue Shield at $220.67, and Aetna at $145.13. UnitedHealth Group is notably lower at $65.62.
Rate dispersion varies significantly across payers. Cigna exhibits the widest spread, with a difference of $258.00 between its 75th and 25th percentiles, indicating substantial variability in reimbursement. In contrast, UnitedHealth Group has the tightest range, with only $25.33 separating its 75th and 25th percentiles, suggesting more consistent rates. The table and chart below present the full breakdown of national benchmarks for each payer.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska demonstrates a wide range in reimbursement rates for CPT code 00148 across major commercial payers. The rate spread, calculated as the difference between the 75th and 25th percentiles, is most significant for Blue Cross Blue Shield, with a spread of $74.80 ($300.60 minus $225.80). Aetna and UnitedHealth Group show minimal rate spread, with all percentiles clustered closely around $72.00, indicating limited variability in their payment structures. Cigna's rates are also tightly grouped, with a spread of $8.00.
When compared to national averages, Blue Cross Blue Shield's mean rate in Alaska is substantially higher, while Cigna and UnitedHealth Group are below their respective national means. The table and chart below present the full breakdown of payer-specific reimbursement rates for CPT code 00148 in Alaska.
Key Insights for Alaska
- Blue Cross Blue Shield offers the highest mean reimbursement rate for CPT 00148 in Alaska at $268.99, while UnitedHealth Group is the lowest at $75.12.
- The rate spread is most pronounced for Blue Cross Blue Shield, with a 75th percentile of $300.60 and a 25th percentile of $225.80, indicating significant variability.
- Compared to national averages, Blue Cross Blue Shield's mean rate in Alaska is notably higher, while Cigna and UnitedHealth Group are below their respective national means.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.